RGIN (Regenicin) Ending Cash Position: $10.88 Mil (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenicin Ending Cash Position?

Regenicin RGIN -99.00% Ending Cash Position is $10.88 Mil as of Mar. 2023.

Regenicin's Ending Cash Position for the quarter that ended in Mar. 2023 was $10.88 Mil.

Regenicin's quarterly Ending Cash Position increased from Sep. 2022 ($0.02 Mil) to Dec. 2022 ($11.79 Mil) but then declined from Dec. 2022 ($11.79 Mil) to Mar. 2023 ($10.88 Mil).

Regenicin's annual Ending Cash Position increased from Sep. 2020 ($0.00 Mil) to Sep. 2021 ($0.00 Mil) and increased from Sep. 2021 ($0.00 Mil) to Sep. 2022 ($0.02 Mil).

Regenicin Ending Cash Position Related Terms

Regenicin Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Regenicin's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenicin Ending Cash Position Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.15 0.00 0.00 0.02

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.02 11.79 10.88

Regenicin Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Regenicin's Ending Cash Position for the fiscal year that ended in Sep. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.002+0.013
=0.02

Regenicin's Ending Cash Position for the quarter that ended in Mar. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=24.327+-13.447
=10.88

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $10.88 Mil mean?
Regenicin (RGIN) has a Ending Cash Position of $10.88 Mil as of Mar. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Regenicin and its competitors.
Is Regenicin's Ending Cash Position too high?
Regenicin's current Ending Cash Position is $10.88 Mil.
How does Regenicin's Ending Cash Position compare to NOVNQ and TMBRQ?
Regenicin's Ending Cash Position of $10.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Regenicin and its competitors. Regenicin's current Ending Cash Position is $10.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenicin stock overvalued right now?
Regenicin (RGIN) has a current Ending Cash Position of $10.88 Mil. The current Ending Cash Position is $10.88 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Regenicin (RGIN), the current Ending Cash Position is $10.88 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenicin Business Description

Address 10530 Discovery Drive, Las Vegas, NV, USA, 89135
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.